(Q70462807)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

title

Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

author name string

M Scudeletti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

M A Imro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

G Motta

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

M Di Gaetano

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

I Pierri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

S Tongiani

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

F Indiveri

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

F Puppo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

publication date

1 July 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

11 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

page(s)

119-124

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf01517044

11 October 2019

exact match

0 references

cites work

In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

1 reference

12 December 2020

Human T lymphocytes in aging and malignancy: abnormalities in PHA-induced Ia antigen expression and in functional activity in autologous and allogeneic MLR

1 reference

12 December 2020

Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically

1 reference

12 December 2020

Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2.

1 reference

12 December 2020

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

12 December 2020

Chemotherapy of lung cancer

1 reference

12 December 2020

A diet enriched in vitamin A acetate orin vivoadministration of interleukin-2 can counteract a tolerogenic stimulus

1 reference

12 December 2020

Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.

1 reference

12 December 2020

Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.

1 reference

12 December 2020

Diagnostic fiberoptic bronchoscopy: Techniques and results of biopsy in 600 patients

1 reference

12 December 2020

Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.

1 reference

12 December 2020

Characterization of CD3+, CD4-, CD8- clones expressing the putative T cell receptor gamma gene product. Analysis of the activation pathways leading to interleukin 2 production and triggering of the lytic machinery

1 reference

12 December 2020

In vivo activity of interleukin-2: conversion of a stimulus causing unresponsiveness to a stimulus causing contact hypersensitivity by the injection of interleukin-2

1 reference

12 December 2020

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

12 December 2020

Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Direct demonstration of the clonogenic potential of every human peripheral blood T cell. Clonal analysis of HLA-DR expression and cytolytic activity

1 reference

12 December 2020

Cancer statistics, 1988

1 reference

12 December 2020

Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer

1 reference

12 December 2020

Immunotherapy with IL2 by Constant Infusion and Weekly Doxorubicin

1 reference

12 December 2020

Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor

1 reference

12 December 2020

Ultrathin needle aspiration of the lung in infectious and malignant disease

1 reference

12 December 2020

Cytotoxic activity and phenotypic characteristics of lymphocyte subsets after therapy of cancer patients with interleukin-2.

1 reference

12 December 2020

Interleukin-2 with Ex Vivo Activated Killer Cells: Therapy of Advanced Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01517044

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8391391%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

1 reference